ЛЕКАРСТВЕННО-ИНДУЦИРОВАННАЯ ГОЛОВНАЯ БОЛЬ (ОБЗОР ЛИТЕРАТУРЫ И РЕКОМЕНДАЦИИ ДЛЯ ПРАКТИКИ)
https://doi.org/10.20514/2226-6704-2023-13-3-175-180
EDN: FEKKPE
Аннотация
Лекарственно-индуцированная головная боль (ЛИГБ) является распространенной вторичной цефалгией, развивающейся у пациентов с частыми и хроническими головными болями при злоупотреблении анальгетическими препаратами и приводящей к значительному ухудшению качества жизни пациентов. Терапия ЛИГБ требует высокой степени комплаентности в отношениях врач-пациент и не всегда приводит к удовлетворительному результату. Поэтому важной задачей является профилактика излишне частого применения симптоматических средств для купирования головной боли. В обзоре представлены современные данные о ЛИГБ, ее лечении и профилактике.
Об авторе
Н. Л. Старикова
ФГБОУ ВО Пермский государственный медицинский университет им. ак. Е.А. Вагнера МЗ РФ
Россия
Россия
Пермь
Список литературы
1. Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care 2019;25(2 Suppl):s23-s34
2. Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalagia 2007; 27(3): 193–210. https://doi.org/10.1111/j.1468-2982.2007.01288.x
3. The International Classification of headache disorders, 3rd edition. Cephalalgia 2018; 38(1): 1-211. doi: 10.1177/0333102417738202
4. Westergaard ML, Munksgaard SB, Bendtsen L, et al. Medicationoveruse headache: a perspective review. Ther Adv Drug Saf 2016; 7(4): 147-158. doi: 10.1177/2042098616653390
5. Diener H-C, Holle D, Solbach K, et al. Nat Rev Neurol 2016; 12(10): 575-583. https://doi.org/10.1038/nrneurol.2016.124
6. Diener H-C, Holle D, Dresler T, et al. Chronic headache due to overuse of analgesics and anti-migraine agents. Dtsch Arztebl Int 2018; 115(22): 365-370. https://doi.org/10.3238/arztebl.2018.0365
7. Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 2018; 38(7): 1316-1325. https://doi.org/10.1177/0333102417736898
8. Salhofer-Polanyi S, Zebenholzer K, Berndl T et al. Medication overuse headache in 787 patients admitted for inpatient treatment over a period of 32 years. Cephalalgia 2020; 40(8): 808-817. doi: 10.1177/0333102420911210
9. Holland PR, Saenjaroentham C, Sureda-Gibert P, et al. Medicationoveruse headache: Divergent effects of new acute antimigraine drugs. Cephalalgia 2020; 40(9): 889-891. doi: 10.1177/0333102420938655
10. Wakerley BR. Medication-overuse headache. Pract Neurol 2019; 19(5): 399-403. https://doi.org/10.1136/practneurol-2018-002048
11. Takahashi TT, Ornello R, Quatrosi G et al. Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain 2021; 22: 32. https://doi.org/10.1186/s10194-021-01224-8
12. Cargnin S, Viana M, Sances G et al. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia 2018; 38(7): 1361-1373. https://doi.org/10.1177/0333102417728244
13. Dodick DW, Silberstein SD. How clinicians can detect, prevent and treat medication overuse headache. Cephalalgia 2008; 28(11): 1107-1242. https://doi.org/10.1111/j.1468-2982.2008.01737.x
14. Nation KM, Dodick DW, Navratilova E, et al. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: Relevance to medication overuse headache. Cephalalgia 2019; 39(5): 617-525. https://doi.org/10.1177/0333102418804157
15. Su M, Yu S. Chronic migraine: A process of dysmodulation and sensitization. Molecular Pain. 2018; 14. doi:10.1177/1744806918767697
16. Chanraud S, Di Scala G, Dilharreguy B, et al. Brain functional connectivity and morphology changes in medication-overuse headache: Clue for dependence-related processes? Cephalalgia 2014; 34(8): 563-639. https://doi.org/10.1177/0333102413519514
17. Galvez-Sánchez CM, Montoro CI, Moreno-Padilla M, et al. Effectiveness of acceptance and commitment therapy in central pain sensitization syndromes: a systematic review. J Clin Med 2021; 10: 2706. https://doi.org/10.3390/jcm10122706
18. Chiang C-C, Schwedt TJ, Wang S-J, et al. Treatment of medicationoveruse headache: A systematic review. Cephalalgia 2016; 36(4): 371-386. doi: 10.1177/0333102415593088
19. Riederer F, Marti M, Luechinger R et al. Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry 2012; 13(7): 517-525. https://doi.org/10.3109/15622975.2012.665175
20. Lai T-H, Chou K-H, Fuh J-L, et al. Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia 2016; 36(14): 1305-1398. https://doi.org/10.1177/0333102416630593
21. Stankewitz A, Schulz E, May A. Neuronal correlates of impaired habituation in response to repeated trigemino-nociceptive but not to olfactory input in migraneurs: an fMRI study. Cephalalgia 2012; 33(4): 256-265. doi: 10.1177/0333102412470215
22. Niddam DM, Lai K-L, Tsai S-Y et al. Brain metabolites in chronic migraine patients with medication overuse headache. Cephalalgia 2020; 40(8): 851-862. https://doi.org/10.1177/0333102420908579
23. Viana M, Bottiroli S, Sances G, et al. Factors associated to chronic migraine with medication overuse: A crosssectional study. Cephalalgia 2018; 38(14): 2045-2057. doi: 10.1177/0333102418761047
24. Hagen K, Linde M, Steiner TJ et al. Risk factors for medicationoveruse headache: An 11-year follow-up study. The Nord-Trondelag Health Studies. Pain 2012; 153: 56-61. https://doi.org/10.1016/j.pain.2011.08.018
25. Lampl C, Thomas H, Tassorelli C, et al. Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain 2016; 17: 59. doi: 10.1186/s10194-016-0649-2
26. Bendtsen L, Munksgaard SB, Tassorelli C, and the COMOESTAS Consortium. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014; 34(6): 426-433. doi: 10.1177/0333102413515338
27. Park H-K, Chu MK, Oh S-Y et al. Interim analysis of the registry for load and management of medication overuse headache (RELEASE): A multicenter, comprehensive medication overuse headache registry. Cephalalgia 2022; 42(6): 455-465. https://doi.org/10.1177/03331024211057184
28. Westergaard ML, Glűmer C, Hansen EH, et al. Medication overuse, healthy lifestyle behavior and stress in chronic headache: Results from a population-based representative survey. Cephalalgia 2016; 36(1): 15-28. doi: 10.1177/0333102415578430
29. Ваганова ЮС, Амелин АВ, Готовчиков АА, Тимофеева АА, Ляшок ПА, Соколов АЮ и др. Клинические особенности пациентов с лекарственно-индуцированной головной болью. Росс Журн Боли 2019; 17(3): 22-28.
30. Vaganova IS, Amelin AV, Gotovchikov AA, Timofeeva AA, Lyashok PA, Sokolov AI. Clinical characteristics of patients with medication overuse headache. Russian J of Pain 2019; 17(3): 22-28. [In Russian].
31. Nielsen M, Carlsen LN, Munksgaard SB et al. Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 2019; 39(7): 863-872. https://doi.org/10.1177/0333102419828994
32. Hagen K, Jensen R, Bøe MG et al. Medication overuse headache: A critical review of end points in recent follow-up studies. J Headache Pain 2010; 11: 373-377. doi: 10.1007/s10194-010-0221-4
33. Evers S, Jensen R. Treatment of medication-overuse headache — guideline of EFNS headache panel. Eur J Neurol 2011; 18(9): 1115-21. doi: 10.1111/j.1468-1331.2011.03497.x.
34. Pensato U, Baraldi C, Favoni V et al. Detoxification vs nondetoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia 2022; 42(7): 645-653. https://doi.org/10.1177/03331024211067791
35. Carlsen LN, Munksgaard SB, Jensen RH, et al. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2018; 38(2): 225-236. doi: 10.1177/0333102417737779
36. Munksgaard SB, Bendtsen L, Jensen RH. Detoxification of medicationoveruse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia 2012; 32: 834-844. https://doi.org/10.1177/0333102412451363
37. Rabe K, Pageler L, Gaul C et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 2013; 33: 202-207. https://doi.org/10.1177/0333102412462638
38. Andrasik F, Grazzi L, Usai S et al. Disability in chronic migraine with medication overuse. Treatment effects through 5 years. Cephalalgia 2010; 30: 610-614. https://doi.org/10.1111/j.14682982.2009.01932.x
39. Сорокина НД, Перцов СС, Савин ЛА, и др. Эффекты транскраниальной магнитной и электростимуляции в терапии болевого синдрома при мигрени и головной боли напряжения. Росс Журн Боли/ 2022; 20(3): 62-68.
40. Sorokina ND, Pertsov SS, Savin LA, et al. Effects of neuromodulation of electroand magnetic neurostimulation in the treatment of pain syndrome in migraine and tension headache. Russian Journal of Pain. 2022; 20(3): 62–68. [In Russian]. https://doi.org/10.17116/pain20222003162
41. Noser AE, Klages KL, Gamwell KL et al. A systematic evaluation of primary headache management apps leveraging behavior change techniques. Cephalalgia 2022; 42(6): 510-523. https://doi.org/10.1177/03331024211053572
42. Lauritsen CG, Silberstein SD. Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review. Cephalalgia 2019; 39(6): 750-760. https://doi.org/10.1177/0333102418796781
43. Bøe MG, Thortveit E, Vatne A, et al. Chronic headache with medication overuse: long-term prognosis after withdrawal therapy. Cephalalgia 2017; 37(13): 1215-1221. https://doi.org/10.1177/0333102416672493
44. Katsarava Z, Muessig M, Dzanidze A et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25: 12-15. https://doi.org/10.1111/j.14682982.2004.00789.x
45. Zidverk-Trajkovic JJ, Pekmezovic T, Jovanovic Z et al. Long-term predictors of remission in patients treated for medicationoveruse headache at a specialized headache center: A prospective cohort study. Cephalalgia 2018; 38(2): 265-273. https://doi.org/10.1177/0333102416683918
46. Diener H-C, Dodick D, Evers S et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019; 18(9): 891-902. doi: 10.1016/S1474-4422(19)30146-2
Рецензия
Для цитирования:
Старикова Н.Л. ЛЕКАРСТВЕННО-ИНДУЦИРОВАННАЯ ГОЛОВНАЯ БОЛЬ (ОБЗОР ЛИТЕРАТУРЫ И РЕКОМЕНДАЦИИ ДЛЯ ПРАКТИКИ). Архивъ внутренней медицины. 2023;13(3):175-180. https://doi.org/10.20514/2226-6704-2023-13-3-175-180. EDN: FEKKPE
For citation:
Starikova N.L. Medication-Overuse Headache (Review of Literature and Recommendations for Practice). The Russian Archives of Internal Medicine. 2023;13(3):175-180. https://doi.org/10.20514/2226-6704-2023-13-3-175-180. EDN: FEKKPE
Просмотров:
592
Послать статью по эл. почте 